These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 32737450

  • 1. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.
    Hestetun KE, Aasebø K, Rosenlund NB, Müller Y, Dahl O, Myklebust MP.
    Mod Pathol; 2021 Jan; 34(1):161-170. PubMed ID: 32737450
    [Abstract] [Full Text] [Related]

  • 2. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
    Qin Q, Zhou AP, Yang L, Xu C, Sun YK, Zhang W, Wang JW, Zhong DS.
    J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
    [Abstract] [Full Text] [Related]

  • 3. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer.
    Ma C, Olevian D, Miller C, Herbst C, Jayachandran P, Kozak MM, Chang DT, Pai RK.
    Mod Pathol; 2019 Jul; 32(8):1217-1231. PubMed ID: 30962505
    [Abstract] [Full Text] [Related]

  • 4. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ.
    J Natl Cancer Inst; 2011 Jun 08; 103(11):863-75. PubMed ID: 21597022
    [Abstract] [Full Text] [Related]

  • 5. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA.
    JAMA Oncol; 2018 Mar 01; 4(3):379-383. PubMed ID: 28983557
    [Abstract] [Full Text] [Related]

  • 6. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, André T.
    Ann Oncol; 2019 Sep 01; 30(9):1466-1471. PubMed ID: 31268130
    [Abstract] [Full Text] [Related]

  • 7. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
    Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S.
    J Clin Oncol; 2010 Jul 10; 28(20):3219-26. PubMed ID: 20498393
    [Abstract] [Full Text] [Related]

  • 8. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
    Qin Q, Ying J, Lyu N, Guo L, Zhi W, Zhou A, Wang J.
    Zhonghua Zhong Liu Za Zhi; 2014 Nov 10; 36(11):844-8. PubMed ID: 25620482
    [Abstract] [Full Text] [Related]

  • 9. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR.
    J Clin Oncol; 2013 Oct 10; 31(29):3664-72. PubMed ID: 24019539
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy.
    Zhao F, Li E, Shen G, Dong Q, Ren D, Wang M, Zhao Y, Liu Z, Ma J, Xie Q, Liu Z, Li Z, Gao L, Zhao J.
    J Gastroenterol; 2023 Jul 10; 58(7):622-632. PubMed ID: 37036516
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Negative CDX2 expression can be an important predictive and prognostic biomarker in stage II colon cancer.
    Bilgin B, Sendur MA, Akinci MB, Yalcin B.
    J BUON; 2017 Jul 10; 22(1):282-283. PubMed ID: 28365970
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
    Williams DS, Mouradov D, Jorissen RN, Newman MR, Amini E, Nickless DK, Teague JA, Fang CG, Palmieri M, Parsons MJ, Sakthianandeswaren A, Li S, Ward RL, Hawkins NJ, Faragher I, Jones IT, Gibbs P, Sieber OM.
    Gut; 2019 Mar 10; 68(3):465-474. PubMed ID: 29382774
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
    Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, Wilcox-Fogel N, Forgó E, Rajendran PS, Miranda SP, Hisamori S, Hutchison J, Kalisky T, Qian D, Wolmark N, Fisher GA, van de Rijn M, Clarke MF.
    N Engl J Med; 2016 Jan 21; 374(3):211-22. PubMed ID: 26789870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.